Yang Li Sells 843 Shares of Surrozen, Inc. (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) VP Yang Li sold 843 shares of the business’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $17.37, for a total value of $14,642.91. Following the transaction, the vice president now owns 13,345 shares of the company’s stock, valued at approximately $231,802.65. The trade was a 5.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Surrozen Price Performance

Shares of NASDAQ:SRZN opened at $12.95 on Wednesday. The company’s fifty day moving average price is $11.08 and its 200-day moving average price is $9.95. Surrozen, Inc. has a one year low of $6.00 and a one year high of $18.17.

Surrozen (NASDAQ:SRZN) last released its earnings results on Wednesday, November 6th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($2.77) by $2.33. The firm had revenue of $10.00 million during the quarter. Equities research analysts predict that Surrozen, Inc. will post -7.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Surrozen

Large investors have recently modified their holdings of the company. CVI Holdings LLC purchased a new stake in Surrozen in the second quarter worth approximately $711,000. Stonepine Capital Management LLC bought a new stake in shares of Surrozen in the 2nd quarter worth approximately $724,000. Nantahala Capital Management LLC purchased a new stake in shares of Surrozen in the 2nd quarter valued at $2,050,000. Finally, Armistice Capital LLC bought a new position in shares of Surrozen during the 2nd quarter valued at $2,080,000. 66.57% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Guggenheim raised Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price objective for the company in a report on Friday, January 3rd.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.